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In recent years, the new direction such as identification of informative circulating markers reflecting molecular genetic changes in the DNA 
of tumor cells was actively developed. Smoking-related DNA adducts are very promising research area, since they indicate high patho-
genetic importance in the lung carcinogenesis and can be identified in biological samples with high accuracy and reliability using highly 
sensitive mass spectrometry methods (TOF/TOF, TOF/MS, MS/MS). The appearance of DNA adducts in blood or tissues is the result 
of the interaction of carcinogenic factors, such as tobacco constituents, and the body reaction which is determined by individual charac-
teristics of metabolic and repair systems. So, DNA adducts may be considered as a cumulative mirror of heterogeneous response of dif-
ferent individuals to smoking carcinogens, which finally could determine the risk for lung cancer. This review is devoted to analysis of the role 
of DNA adducts in lung carcinogenesis in order to demonstrate their usefulness as cancer associated markers. Currently, there are some 
serious limitations impeding the widespread use of DNA adducts as cancer biomarkers, due to failure of standardization of mass spec-
trometry analysis in order to correctly measure the adduct level in each individual. However, it is known that all DNA adducts are im-
munogenic, their accumulation over some threshold concentration leads to the appearance of long-living autoantibodies. Thus, detection 
of an informative pattern of autoantibodies against DNA adducts using innovative multiplex ELISA immunoassay may be a promising 
approach to find lung cancer at an early stage in high-risk groups (smokers, manufacturing workers, urban dwellers).
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INTRODUCTION
Cancer is one of the leading causes of death in the 
world, accounting for over 25% of all deaths in developed 
countries. Lung cancer (LC) holds the top position in can-
cer morbidity and mortality among men worldwide. The 
both sexes combined, LC incidence rate was 23.1 cas-
es/100 000 in the world and 28.7/100 000 cases in Central 
and Eastern European countries. The LC mortality world-
wide was 19.7 cases/100 000 vs 24.1  cases/100 000 in Eu-
rope [1]. At the same time, the mortality during the first 
year after diagnosis is very high and is about 67%. 
Success of surgical treatment is closely related to the 
opportunity for early diagnosis of LC. The importance 
of early diagnosis is confirmed by the 5-year survival rate 
after radical surgery. People diagnosed with stage I and 
II of LC tend to have higher 5-year survival rate (63.5%, 
and 43.5%, respectively) than people diagnosed with 
stage III (22.9%) [1, 2].
Computed tomography is usually used for diagno-
sis and screening of LC, but this method has several 
disadvantages such as a high cost and low availability 
as well as a lack of sensitivity and specifi city. Diagnostic 
errors occur in 25% of cases resulting in treatment delay 
of up to one year. Usage of new diagnostic methods, 
i.e. positron emission tomography (PET) and autofluo-
rescence bronchoscopy for the detection of LC has not 
reduced the mortality [3] due to the low efficiency of these 
methods at early stages of the disease.
The usage of circulating tumor-associated molecular 
markers in combination with the methods of instrumental 
imaging is one of the most promising trends for impro ving 
the effectiveness of early diagnosis of LC [4]. Specific 
molecular markers can also be used for diffe rential diag-
nosis of LC and other pathological processes in lung, for 
detection of drug resistance formation, to adapt treatment 
accordingly depending on what the chemotherapy drug 
can be changed [5]. There are several circulating protein 
markers which are practically used in diagnostics and 
monitoring of LC, namely, CEA (carcino-embrionic anti-
gen), CYFRA-21–1 (CYtokeratin FRAgment), TPA (tissue 
plasminogen activator), Pro-GRP (pro-gastrin-releasing 
peptide), NSE (neuron-specific enolase). However, cur-
rent serological markers of LC have very low sensitivity. 
For example, CEA, NSE, CYFRA-21–1 measurement can 
detect non-small cell LC with a sensitivity of 55; 38 and 
65% and specificity of 70; 97 and 87%, respectively [6].
In recent years, the new direction such as identification 
of informative circulating markers reflecting molecular 
genetic changes in the DNA of tumor cells is actively 
deve loped. There is a large number of reviews high lighting 
the possibility of using circulating tumor DNA for the di-
agnosis and prediction of clinical course of cancer [7–9].
These markers include tumor-specific mutations, 
chromosomal aberration, methylated DNA fragments, 
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and DNA adducts caused by tobacco smoke carcinogens 
as a main etiologic factor of LC.
DNA adducts are very promising research area, since 
their chemical structures are considerably diffe rent from 
mutated or methylated DNA and can be identified in clini-
cal samples with high accuracy and reliability. Currently, 
there are highly sensitive mass spectrometry methods 
(TOF/TOF, TOF/MS, MS/MS), to identify and quantify 
smoking-related DNA adducts [10]. Continuously up-
dated information about the genotoxic effect of tobacco 
smoke components indicates their high pathogenetic 
importance in the tumor formation.
This review is devoted to the analysis of the role of DNA 
adducts in lung carcinogenesis in order to demonstrate 
their usefulness as noninvasive cancer associated mark-
ers. The perspective to use them as cancer markers 
is provided by their crucial role in smoking-related lung 
carcinoge nesis. The further investigations using mass 
spectrometry analysis are needed to identify the most 
important DNA adducts reflecting the risk of cancer devel-
opment. DNA adducts are known to be high immunogenic 
substances resulting in the autoantibody formation in the 
blood. The testing of autoantibodies against reliable DNA 
adducts may be considered as a promising way for early 
detection of LC, however further studies are required 
to demonstrate clinical validity and utility for this approach.
THE ROLE OF TOBACCO SMOKING 
IN THE PATHOGENESIS OF LUNG CANCER
Complex composition of tobacco smoke makes 
difficult to identify the mechanisms that trigger the pro-
cess of carcinogenesis. Approximately 20 substances 
in cigarette smoke have a carcinogenic effect, which are 
represented by polycyclic aromatic hydrocarbons (PAHs), 
nitrosamines, aldehydes, etc. [11]. All of them are on the 
list of carcinogens released by IARC (International Agency 
for Research on Cancer) [12]. In this review, we made 
an attempt to summarize the mechanisms of carcino-
genic action of tobacco smoke components that can 
cause genetic alterations in oncogenes and tumor sup-
pressor genes, as well as to show the possible causes 
of the heterogeneity of the negative effects of smoking 
in different subjects.
Nicotine, compound which is found in large quantities 
in tobacco, has no carcinogenic effect, but it is a highly 
addictive substance that leads to a constant consump-
tion and accumulation of other carcinogens of tobacco 
smoke in the body. Some of the major components 
of tobacco smoke such as PAHs and nitrosamines are 
not carcinogens initially they need metabolic activation 
to acquire carcinogenic properties. Imbalance between 
metabolic activation and detoxification may lead to an in-
creased risk of LC [13]. Normally, the cell with damaged 
DNA commits suicide by apoptosis, but if these mutations 
occur continuously in the critical region of an oncogene, 
this may lead to activation and accumulation of aberrant 
cells with a loss of cell cycle regulation, and as a result 
to malignant transformation.
Molecular genetic changes in LC inducing by tobacco 
smoking are represented by the following events: chro-
mosomal aberrations, point mutations, dysregulation 
of oncogenic signal transduction pathways, DNA methyla-
tion, etc. Active or passive exposure to tobacco smoking 
equally causes multiple cytogenetic changes, including 
different types of DNA and chromosome damage. Point 
mutations in oncogenes and tumor suppressor genes are 
quite frequently detected in the tumor tissue of LC patients 
who are former smo kers. Accor ding to published data, 
TP53 mutations are associated with exposure to tobacco 
smoke and may cause disruption of its functional activity.
The increased frequency of nucleotide substitution 
of thymine to guanine in TP53 gene in LC smokers often 
observed in the so-called “hot spots” which are located 
at 157, 158, 245, 248 and 273 codons [14–16]. It has been 
experimentally proved that the appearance of such nucle-
otide substitution may be caused by the action of tobacco 
smoke metabolite benzo[a]pyrene — benzopyrene-7,8-
diol-9,10-epoxi de (BPDE) le ading to formation DNA ad-
ducts in these regions [16, 17].
Methylation of several suppressor genes, namely, 
CDKN2A (cyclin-dependent kinase inhibitor 2A), 
DAPK1 (death-associated protein kinase 1), RASSF1A 
(Ras association domain family 1 isoform), RARb2 (reti-
noic acid receptor B2), APC (adenomatous polyposis 
coli), CDH13 (cadherin 13), MGMT (O(6)-methylguanine-
DNA methyltransferase), MLH1 (MutL homolog 1), 
MSH2 (MutS protein homolog 2) and GSTP1(glutation-
S-transferase P 1) resulting in their inactivation has been 
found in LC [18]. Number of studies demonstrate that 
methylation of the CDKN2A gene is much less common 
in non-smoking patients with LC, indicating a direct link 
with smoking. Also, a lower rate of the APC gene methy-
lation (p < 0.0001) was found in patients who had never 
smoked. Methylated forms of these genes are detected 
in DNA from sputum, bronchoalveolar lavage fluid and 
serum, suggesting the possibi lity of their use for minimally 
invasive screening. The possible significance of these 
markers as risk factors for LC is shown in examples 
of RARB2 and CDKN2A genes, their methylated forms 
are detected in bronchial biopsy samples of smokers 
without tumor and serum of patients with an increased 
risk of LC, and in serum of squamous cell lung carcinoma 
patients 3 years before the clinical manifestation [19, 20]. 
Prognostic role of methyla ted DNA fragments of RASSF1A 
and RARb2 suppressor genes in serum patients with 
squamous LC was shown in relation to risk of relapse after 
combined treatment [21, 22].
The active components of tobacco smoke affect basic 
cellular functions, such as cell response to DNA damage, 
induction of oxidative stress, apoptosis and inflammatory 
reactions. Taking into account the involvement in these 
processes a large number of functionally important genes 
and signaling pathways necessary is to clarify the initial 
changes caused by metabolites of tobacco smoke that 
can further lead to tumor formation.
Oxidative stress is a result of an imbalance between 
the formation of reactive oxygen species (ROS) and 
a biological system’s ability to readily detoxify the reactive 
intermediates or to repair the resulting da mage. Oxidative 
stress is an important pheno menon in the pathophysio-
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logy of cancer [23]. Oxidative stress induced by the 
tobacco smoke components leads to DNA strand breaks 
and oxidative modification of DNA. Tobacco smoke 
contains a large number of free radicals which cause 
DNA damage and gene rate oxidized base forms such 
as 7,8-dihydro-8-oxo-2-deoxyguanosine (8-OH-dG), 
which is a classical biomarker of oxidative DNA damage. 
Inflammatory response induced by damaging effect 
of tobacco smoke creates certain conditions in micro-
environment that enhances carcinogenesis [24]. These 
conditions include glutathione oxidation, followed by in-
creasing of glutathione disulfide level in the lung tissue 
and bronchoalveolar lavage fluid; increase in 8-OH-DG, 
overexpression of mRNA of nitric oxide synthase and 
endothelial nitric oxide synthase genes in the lung tissue; 
reduction of antioxidants in the blood, such as methy-
lumbelliferone glucuronide and ferroxidase; increa-
sing lipid peroxidation indicators (8-Epi-prostaglandin 
F2 alpha); increasing oxygen removing from leukocytes 
in bronchoalveolar lavage fluid [25]. All these processes 
contribute to the accumulation of genotoxic damage 
and the development of chronic inflammatory response 
aimed at preserving tissue integration, triggering pro-
cesses of repair and regeneration, similar to wound 
healing. In this case, the inflammatory response performs 
the tumor-promoting function by production of growth, 
anti-apoptotic, pro-angiogenic and matrix remodeling 
factors [26].
Recent studies have shown that mutations or aber-
rant expression of miRNAs that are negative post-trans-
criptional regulators of gene expression associated 
with various human diseases, including cancer. Various 
researches on non-small cell LC samples established 
the potential association between the expression of dif-
ferent miRNAs and action components of tobacco smoke. 
For example, expression of  miR-218 significantly reduced 
in the tumors of patients — current or former smokers, 
while in tumors of patients who has never smoked such 
changes were not detected. Another study showed a sig-
nificant difference in the expression levels of  miR-130a 
between smo king and nonsmoking patients with LC [27]. 
In a recent study it was found that the expression level 
of miR-143 was lower in smokers than non-smokers 
patients, as the authors suggest,  miR-143 may play 
a significant role in the etiology of LC [28]. In contrast 
to the above, microarray study performed by Landi et al. 
did not reveal any significant differences in the miRNAs 
expression in smokers and non-smoking patients with 
LC [29]. Inconsistency of the results can be explained 
by a small number of the samples. Probably more de-
tailed study with strict stratification of patients according 
to histological type of tumor, smoking status, gender 
is required.
Still it has not been reliably established, whether to-
bacco smoke-induced LC characterized by special mo-
lecular signature or all of the molecular changes in LC are 
universal. Detection of specific genetic and epigenetic 
abnormalities induced by tobacco smoke will allow iden-
tifying the key genes associated with potentially high risk 
for LC. This will help to carry out monitoring of patients with 
pre-cancerous conditions of the lung for the early detec-
tion of the disease and to plan strategies for prevention.
CAUSES OF HETEROGENEITY 
IN THE NEGATIVE EFFECTS OF SMOKING
The role of smoking in LC development was finally 
proved only in the 60s of the last century, because it was 
unclear why incidence of LC in smokers was extremely 
low and amounted to only 10%. The subsequent develop-
ment of molecular biological research methods allowed 
comes closer to the cause of such ambiguity. Appar-
ently, genetically determined (or inherited) characteristics 
of metabolic system, as well as DNA repair system, make 
a significant contribution to the risk of LC. In particular 
tobacco smoke carcinogens undergo complex metabolic 
conversions, usually via series of chemical reactions. 
It is known that people who inherited different polymor-
phic variants of genes encoding enzymes involved in car-
cinogen metabolism characterized by different degrees 
of resistance to their action and, accordingly, various risk 
of LC development [30–32].
After entering the body PAH molecules induce the ex-
pression of Phase I and Phase II metabolic enzymes [33], 
including aldo-keto reductases, cytochrome P450, 
catechol-O-methyltransferase, epoxide hydrolases, 
peroxidases, glutathione S-transferase (GSTM1), N-
acetyltransferases, sulfotransferases, and other enzymes 
which catalyze the conjugation reaction [34]. The most 
common mechanism of PAH metabolic activation, for 
example, benzo[a]pyrene, is the formation of the dihydro-
diol epoxide — BPDE, which is catalyzed by cytochrome 
P450 enzymes and epoxide. The main enzymes which 
involved in PAHs metabolism are Cytochromes P450 CYP 
1A1, CYP 1A2, CYP 1B1 and CYP 3A4. Induction of these 
enzymes is significantly increased in the presence 
of benzo[a]pyrene and some polyhalogenated hydro-
carbons. People who have inherited low-activity variants 
of cytochrome are relatively resistant to tobacco smoke 
carcinogens. In particular, it has been found that some 
polymorphic variants of CYP 1A gene associated with 
increased formation of DNA adducts and mutagenesis 
in some populations [35].
Subsequent phase of PAH metabolism includes 
conjugation of phase I metabolites with small mo lecules. 
Enzymes catalyzing phase II include sulfotransferase, 
UDP (Uridine 5’-diphospho)-glucuronyl transferase and 
glutathione-S-transferase. Sulfotransferases (SULT) 
involved in the activation of such PAH metabolites 
as 7, 12-dimethylbenz(a)anthracene and its methyl-
hydroxylated derivatives in various tissues. It is shown 
that polymorphic variants of sulfotransferase SULT1A1 are 
associated with different levels of DNA adducts forma-
tion [36]. Conjugation of PAH metabolites with glucuronic 
acid (glucuronidation) is also one of the main way of de-
toxification resulting in formation of polar conjugates, 
which have higher excretion rate. Oxidized derivatives 
of benzo[a]pyrene (for example, 1-hydroxypyridine) are 
a substrate for UDP-glucuronosyltransferase. The re-
sulting compound 1-hydroxypyrene glucuronide can 
be used as biomarker of PAH exposure [37]. Glutathione-
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S-transferase is also involved in the conjugation pro-
cesses of PAH derivatives. Study conducted on placental 
tissue samples showed that the activity of glutathione-S-
transferase determined by glutathione redox status and 
the presence of genotoxic da mage that may be used 
as a marker for the damaging effects of PAHs [38].
Polymorphisms in phase II metabolic enzymes genes 
are correlated with the amount of DNA da mage and, there-
fore, with a risk of malignization. Thus, Binkova et al. [39] 
demonstrated an association between the polymorphic 
variants of a glutathione-S-transferase and the amount 
of DNA adducts. Individuals who have functionally inacti-
vated glutathione transferase μ gene characterized by in-
creased susceptibility to LC. It is not surprising that the most 
dangerous is combination of unfavorable genotypes of CYP 
1A1 and GSTM1; individuals with such combination have 
2-fold increased risk of LC development [40, 41].
The contribution of the genetic component in the for-
mation of LC risk is not limited to only the genes respon-
sible for the metabolic activation of tobacco smoke 
components. A significant role is also played by the indi-
vidual characteristics of the DNA repair system. The most 
common mechanisms of cell repair include: nucleotide 
excision repair (NER), base excision repair (BER), non-
homologous end joining (NHEJ), homologous recombi-
nation repair (HRR), transcription coupled repair (TCR). 
Several studies have shown that polymorphisms of certain 
genes of NER increase the efficiency of repair [42].
Four known polymorphism — 4G/A substitution in XPA 
(xeroderma pigmentosum, complementation group A) 
gene, C8092A in ERCC1 (excision repair cross-comple-
mentation group 1) gene, Lys751Gln in XPD (xeroderma 
pigmentosum group D, ERCC2) gene and Ser835Ser 
in XPF (xeroderma pigmentosum group F, ERCC4) gene 
are associated with reduced DNA repair capacity and 
increased incidence of tumors of various types [43].
Recent studies have shown that BER plays a special role 
in the repair of damage produced by the action of PAHs. 
It was found that the CHO (Chinese hamster ovary) cell 
line deficient in BER genes more sensitive to 11,12-dihy-
droxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a,l]
pyrene (DBPDE), resulting in an increase in the frequency 
of chromosome  aberrations [44]. Polymorphic variants 
of BER genes are associated with an increased incidence 
of DNA damage. Thus, the product of the XRCC1 (X-ray re-
pair cross-complementing protein 1) gene has 4 functional 
polymorphic variants — T77C, Arg194Trp, Arg280His and 
Arg399Gln [45], which are associated with altered ability 
to repair DNA damage caused by PAH action [46].
Polymorphisms of proteins involved in HRR, is probably 
able to protect the effects of PAHs. One of these proteins, 
XRCC3, is involved in homologous recombination repair 
of double strand breaks and removing of double bonds 
(cross-linking) between guanine bases belonging to diffe-
rent chains. According to Shen et al. (2003), polymor-
phism of XRCC3 codon 241 is protective for bladder can-
cer, especially for long-term smokers [47]. Considering 
that tobacco smoke contains a large number of PAH, this 
fact allows making sure that HRR involved in repair of DNA 
lesions induced by exposure to PAHs. Furthermore, it has 
been shown in vitro that CHO cell line deficient in HR genes 
are more susceptible to the adverse effects of PAHs, which 
also confirms the data of the important role of homologous 
recombination in DNA repair [44].
DNA ADDUCTS AS MARKERS OF LUNG 
CANCER RISK
Polycyclic aromatic hydrocarbons. Initially PAHs 
are absolutely inert substances and acquire their biologi-
cal activity only after metabolic activation. Among PAHs, 
benzo[a]pyrene is the well-studied compound and its 
ability to induce lung tumors when administered topically 
and inhaled well described [48].
Benzo[a]pyrene forms at least nine different DNA 
adducts which have been characterized and isolated 
from body fluids (saliva, urine, blood), lung, liver and 
cells of human and animals. Different types of adducts 
were determined by mass spectrometry and were 
shown specific sites of DNA damage. There are three 
metabolic pathways of benzo[a]pyrene activation — 
formation of a radical cation, diol epoxide and ortho-
quinone [49]. The third pathway leads to the formation 
of reactive metabolite — benzo[a]pyrene-7,8-dione 
by oxidation of benzo[a]pyrene-7,8-trans-dihydrodiol 
catalyzed by aldo-keto reductases. Thus, it was shown that 
H358 cells produce large amount of benzopyrene-7,8-
dione under exposure to  benzo[a]pyrene. In subsequent 
experiments it was found that 7,8-benzopyrene-dione 
DNA-adducts detected in immortalized HBEC-KT cells 
and in human lung adenocarcinoma cells A549. Wherein 
A549 cells mainly produce adducts of 2’-deoxyguanosine 
(dGuo), while HBEC-KT cell lines — 2’-deoxyadenosine 
(dAde). Mass spectrometric study allowed to identify 
several stable benzo[a]pyrene-7,8-dione adducts: hy-
drated forms of benzo[a]pyrene 7,8-dione-N2-dGuo 
and benzo[a]pyrene-7,8-dione-N1-dGuo in A549 cells; 
hydrated and unhydrated forms of benzo[a]pyrene-7,8-
dione-N1-dAde and benzo[a]pyrene-7,8-dione-N3-dAde 
in HBEC-KT cells.
Another product of benzo[a]pyrene metabolic ac-
tivation is benzopyrene-7,8-diol-9,10-epoxide. All diol 
epoxides exist as diasteromers, i.e. stereoisomers that are 
not mirror images of each other, and referred to as anti-
BPDE and syn-BPDE, each of which at one time may 
be represented by two (+/−) enantiomers. The experiment 
conducted by Buening et al. showed that isomer (+) — 
anti-BPDE has the greatest tumorigenicity in vivo [50]. 
It is known that indicated isomer interacts with N2-atom 
of deoxyguanosine forming (+)-trans, (+)-cis-BPDE-N2-
dG, and (−)-trans and (−)-cis-BPDE-N2-dG adducts. 
Of these four adducts (+)-cis-BPDE- N2-dG is the most 
common and its presence is registered in 45% of smokers. 
Presence of BPDE-DNA adducts in human tissues has 
been reliably established [51] and shown to be the  highest 
concentration in the bronchial epithelium, indicating a di-
rect role in the initiation of LC [52].
Aromatic amines. Aromatic amines contained 
in the tobacco smoke can also be sources for DNA adduct 
formation. The most studied aromatic amine in tobacco 
smoke is a 4-aminobiphenyl (4-ABP) [53]. A recent study 
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authored by Lee et al. found that 4-ABP-adducts are 
formed mainly in the mutational hot spots of TP53 gene 
(codons 280 and 285) in a human bladder cancer cell 
line [53]. These results confirm pathogenic role of 4-ABP-
adducts in the development of bladder cancer. Using 
of sensitive immunobiological and mass spectrometric 
methods allows  detecting the presence of DNA and pro-
tein 4-ABP-adducts in various human tissues resulting 
from exposure to tobacco smoke.
It is interesting that in intact breast tissue adjacent 
to the tumor, level of 4-ABP-adducts correlated with smo-
king status. In biopsies obtained from patients with bladder 
cancer quantity of DNA adducts were also associated with 
smoking and the tumor size. However, the results ob-
tained in studies of different groups of patients are rather 
contradictory. Thus, using of HPLC (high-performance 
liquid chromatography) method, followed by tandem 
mass spectrometry does not allowed the identification 
of 4-ABP-adducts in biopsies of 70 breast cancer patients. 
Perhaps this may be due to incorrect grouping of patients, 
as a systema tic survey and detection of patient’s smoking 
status has not been established. The few studies of aro-
matic amines DNA adducts in the tissues of smokers and 
non-smokers LC patients are also characteri zed as a highly 
controversial [54].
Aldehydes. Acrolein (2-propenal) — highly reactive 
unsaturated aldehyde contained in thermally processed 
foods and in the environment, as the pro duct of incom-
plete combustion of gasoline, plastic and wood. Tobacco 
smoke contains approximately 180 mg of acrolein per 
cigarette, which is 1000 times greater than the PAHs 
content. In this case, unlike PAHs, acrolein is initially ac-
tive component capable of providing a damaging effect. 
Acrolein has a mutagenic effect toward bacterial and 
mammalian cells. Acrolein binds deoxyguanosine forming 
one of two stereoisomers, 1,N2-propanodeoxyguanosine 
(Acr-dGuo) — α-OH-Acr-dGuo and γ-OH-Acr-dGuo. 
Highest mutagenic effect has α-isomer which induce 
G>T substitutions in CpG-islands, mainly, in TP53 codons 
249 and 273 [55].
One of the first studies authored by Nath et al. (1998) 
demonstrated a significant increase of Acr-dGuo adducts 
in epithelial cells of the oral mucosa in smokers [56]. 
Based on the similarity of the mechanisms of acrolein and 
PAHs action, many authors have suggested that indicated 
major component of tobacco smoke may be responsible 
for the TP53 gene mutations in lung cancer associated 
with smoking. To detect the presence of acrolein ad-
ducts in the lung tissue and to evaluate their contribu-
tion in the pathogenesis of LC, Zhang et al. developed 
a methodo logical approach based on liquid chromatogra-
phy and tandem mass spectrometry to quantify Acr-dGuo 
in biological samples [57]. They analyzed 30 samples 
of normal lung tissue and detected the presence of both 
stereoisomers in all samples irrespective of smoking status. 
In the next study, the presence of Acr-dGuo adducts was 
evaluated in peripheral blood lymphocytes of 25 smokers 
and 25 non-smokers. Predominant presence γ-isomer 
was detected in all samples except three patients. 
However, significant differences between smokers and 
non-smo kers were not found. Paradoxically, the average 
content of γ-OH-Acr-dGuo was statistically higher in non-
smokers. Based on these results, the authors conclude 
that acrolein probably undergoes detoxification with a very 
high efficiency by conjugation with glutathione. Obviously, 
the most damaging effect of acrolein adducts, promoting 
malignant transformation of epithelial cells of the lung, 
is the inhibition of NER, which is responsible for the removal 
of DNA damage caused by the action of PAHs [55].
Acetaldehyde is the one of the most common carcino-
gens in tobacco smoke, may also be present in foods and 
in products of combustion. A certain amount of acetal-
dehyde is formed endogenously in threonine catabolism 
and metabolism of ethanol. Acetaldehyde binds DNA 
forming N2-ethylidene-dGuo. After enzymatic hydrolysis 
of DNA in the pre sence of NaBH3CN indicated metabo-
lite forms N2-ethyl-dGuo, which can be detect by mass 
spectrometry [58]. Theoretically, N2-ethylidene-dGuo 
may undergo a subsequent transformation forming 1,N2-
propanodeoxyguanosine (the same adduct formation 
occurs under the exposure of acrolein). The proof of this 
hypothesis serves an experiment in vivo conducted 
by Wang et al. (2006) [58]. 1,N2-propanodeoxyguanosine 
can be detected in the cells after exposure to micromolar 
concentrations of acetaldehyde. Probably acetaldehyde 
adducts play a role in the carcinogenic effect of tobacco 
smoke, but the contribution of this component to the over-
all genotoxicity should be clarified in further studies.
The evidence exists that, among other components 
there are some ethylating agents in a tobacco smoke 
whose structure has not yet been established [59]. When 
studying normal lung epithelium obtained from patients 
with LC, O4-etiltimidin was detected in 10 of 13 smokers 
and only 3 out of 11 non-smoking subjects. Another study 
on a small group of patients de monstrated the presence 
of the O4-ethyltimidine in sputum from two of four smokers 
and was not detected in either of the samples obtained 
from nonsmokers [60].
Nitrosamines. Significant contribution to the study 
of nitrosamines metabolism contained in tobacco smoke 
was made by Hecht and co-authors [61]. For metabolite 
identification the authors used the HPLC-electrospray 
ionization-MS-MS analysis in vitro and in vivo studies. 
It was found that these chemicals act as bidentate (ligand 
that binds through two sites) carcinogens. Contained 
in cigarette smoke nitrosamine 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) undergoes metabolic 
activation, forming 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL). The further reaction consists of con-
version of intermediate metabolite to methanediazo-
hydroxid, which in its turn interacts with DNA and forms 
O6-methyl-dGuo, 7-methyl-dGuo and O6-methyl-dThd. 
O6-methyl-dGuo has the highest mutagenic effect [62]. 
In addition to the well-studied pathway of activation, 
leading to the formation of a methylating agent, there 
is another mechanism which results in the formation 
of pyridyloxobutyla ting agent. Another nitrosamine — 
N-nitrosonornicotine (NNN) also produces two types 
of reactive agents. Both compounds have a pronounced 
carcinogenic effect in animal models, forming tumors with 
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similar localization to smokers with LC [63]. Pathway which 
associated with pyridyloxobutylation leads to the formation 
of a large number of adducts: 7-[4-(3-pyridyl)-4-oxobut-
1-yl]-2´-deoxyguanosine (7-pobdG), O2-[4-(3-pyridyl)-
4-oxobut-1-yl]-2´-deoxycytosine(O2-pobdC), O2-[4-(3-
pyridyl)-4-oxobut-1-yl]-2´-deoxythymidine(O2-pobdT), 
O6-[4-(3-Pyridyl)-4-Oxobut-1-yl]-2´-Dexoyguanosine 
(O6-pobdG). Two of these adducts — 7-pobdG and O2-
pobdC release appropriate nitrogenous base,  forming 
7-[4-(3-pyridyl)-4-oxobut-1-yl]-guanine ( 7-pobG) 
and O2-[4-(3-pyridyl)-4-oxobut-1-yl]-cytosine (O2-
pobC). The presence of all these adducts was detected 
in the tissues of rodents after admini stration of NNN 
and NNK. Moreover, the maximum concentration was 
detected in lung, liver and then, in mucosa of the nasal 
cavity and pancreas. If one considers the ratio of different 
adducts their distribution in the lung tissue, was as follows: 
O2-pobdT≥7-pobG>O2-pobC>> O6-pobdG.
Interestingly, the study of the content of these adducts 
in tissues of patients with LC have not been conducted. 
These data could clarify the role of nitrosamines in the 
pathogenesis of LC associated with smoking. Study of Bes-
sette et al. [64] demonstrated that N-(deoxyguanosine-
8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]
pyridine was detected in saliva samples of 13 out 
of 29 smokers and only in 2 out of 8 samples of non-
smokers, while а N-(deoxyguanosin-8-yl)-2-amino-9H-
pyrido[2,3-b]indole and N-(deoxyguanosin-8-yl)-
2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline were 
detected in saliva samples only in three smokers and 
 N-(deoxyguanosin-8-yl)-4–4-aminobiphenyl was de-
tected in saliva of two smokers. The levels of these various 
adducts ranged from 1 to 9 adducts per 108 base pairs.
Formaldehyde. Recent mass-spectrometric stu-
dies comparing the level of formaldehyde DNA adduct 
in smokers and non-smokers showed that the level 
of N6-hydroxymethyldeoxyadenosine (N6-HOMe-dAdo) 
in smokers was higher than in non-smokers [65], that 
may indicate a role of formaldehyde in the pathogenesis 
of LC induced by smoking.
Formaldehyde is also a component of tobacco 
smoke, which is classified as carcinogenic and genotoxic 
agent, forming DNA adducts. Meta-analysis conducted 
by US researchers of more than 25 thousand manufactu-
ring workers who are exposed to formal dehyde, showed 
a significant increase in the risk of leukemia. In the study 
held by Wang et al. quantity of N6-HOME-dAdo was 
measured using mass spectrometry in leukocyte DNA 
from 32 smo kers and 30 non-smokers [65]. The presence 
of this adduct was detected in 21 out of 29 smokers (179 ± 
205 fmol/μmol dAdo) and only in 7 out of 30 non-smokers 
(15.5 ± 33.8 fmol/μmol dAdo). However, the study 
of Lu et al. [66] showed that formaldehyde metabolites 
form DNA adducts, preferably binding to deoxyguano-
sine and forms unstable N2-hydroxymethyl-dGuo, which 
is converted in N2 -methyl-dGuo in the presence of so-
dium cyanoborohydride. At the same time, the presence 
of formaldehyde adducts detected mainly in the mucosa 
of the nasal cavity, lung tissue, but not in distant organs 
such as liver, spleen, bone marrow.
Estimation of the contribution of formaldehyde adducts 
inhaled with tobacco smoke, complicated by the fact that 
all cells of the organism contain endogenous formalde-
hyde and, accordingly, its adducts. Therefore, while stu-
dying the biological effects of exo genous formaldehyde 
it is necessary to carry out its radioactive labeling.
CONCLUSION
Analysis of recent data has demonstrated that DNA-
adducts may be potential markers of LC risk. The appear-
ance of DNA adducts in blood or tissues is the result of the 
interaction of carcinogenic factors, such as tobacco constitu-
ents, and the body reaction which is determined by individual 
characteristics of me tabolic and repair systems. An important 
fact is that initially most carcinogens of tobacco smoke are 
inert substances and acquire their genotoxic activity only 
after metabolic activation. Thus, the ultimate carcinogenic 
effect of tobacco constituents (initiation of malignancy) 
manifests as a result of their genotoxic action which can 
be considerably modified by the functioning of the repair 
systems. So, DNA adducts may be consi dered as a cu-
mulative mirror of heterogeneous response of different 
individuals to smoking carcinogens, which finally could 
provide the risk for LC.
At the current moment, there are some difficulties 
impeding the widespread use of DNA adducts as cancer 
biomarkers. Firstly, there are no analytical standards 
of substance for quantitative determination of DNA ad-
ducts, except for the most common 8-oxo-dG. For the rest 
of the substances it is necessary to develop commercially 
available standards, including deuterated forms. Third, 
in order to detect the increased level of DNA-adducts, 
it is required to establish background values, because 
some adducts may be formed endogenous. The level 
of background DNA damage formed as a result of some 
endogenous processes may reach 1 to 105 according 
to some reports [67]. Furthermore, the same DNA-ad-
ducts can be formed by several pathways, so 8-oxo-dG, 
may be produced by exposure to benzo[a]pyrene, as well 
as to carbon tetrachloride [68, 69]. In our opinion, further 
studies are needed to establish the laws of the content 
of individual adducts in tissues and biological fluids of pa-
tients, as well as their concentration.
Using of common research method of mass spectro-
metry as a routine method in clinical laboratory is economi-
cally unjustified. Therefore, for the realization of the early 
detection of LC it is necessary to develop an appropriate 
method. It is known that all DNA adducts are immuno-
genic, their accumulation to some threshold concentration 
leads to the appe arance of long-living autoantibodies [70, 
71]. Over the past year, incre asing attention has focused 
on the possibility to detect autoantibodies against DNA 
adducts, in particular adducts of benzo[a]pyrene [72–74]. 
Thus, identification of autoantibodies to DNA adducts may 
be a promising approach for early diagnosis of LC in high-
risk groups (smo kers, manufacturing workers, urban 
dwellers). The use of high effective multiplex ELISA im-
munoassay will allow the numerous autoantibodies against 
different DNA adducts to be detected in order to increase 
the method sensitivity.
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